• Pancreatic Cancer Roundtable - Expert Perspectives: Selecting Initial Treatment Strategies in Pancreatic Cancer
  • Begin Now
  • CNE Activity - Research, Advocacy and Practice: Working Together to Impact Outcomes in Pancreatic Cancer
  • Begin CE Activity
  • Earn CME Now
  • View New CE Activity Now
  • New Options, New Hope: Recent Chemotherapeutic Advances in Metastatic Pancreatic Cancer

What's New

CNE Education
Research, Advocacy and Practice: Working Together to Impact Outcomes in Pancreatic Cancer
Eileen M. O’Reilly, MD, Anitra Engebretson, Mary Griffin Strom, MSN, RN
CE Education
Empowering Community Oncologists in the New Era of Cancer Management:
ADAPTATION OF THE IMMUNO-ONCOLOGY REGIONAL MEETING SERIES

Bradley C. Carthon, MD, PhD; Jason J. Luke, MD, FACP; Jeffrey S. Weber, MD, PhD
CE Education
Individualizing Therapeutic Options and Achieving Goals in Chronic Lymphocytic Leukemia (CLL)
Jan A. Burger, MD, PhD; Jennifer R. Brown, MD, PhD; Peter Hillmen, MD, FRCP, FRCPath, PhD; Thomas J. Kipps, MD
CE Education
Expert Strategies in Mantle Cell Lymphoma: Age-based Differential Approaches to Induction Therapy
Julie M. Vose, MD, MBA – Chair; John P. Leonard, MD; Brad S. Kahl, MD
CE Education
Evolving Treatment Paradigms in Chronic Lymphocytic Leukemia: Challenging Cases and Expert Strategies
Susan M. O’Brien, MD – Chair; John C. Byrd, MD; Nicole Lamanna, MD
CE Education
Aligning Current Practice in Febrile Neutropenia with Guideline-based Care
James O. Armitage, MD – Moderator; R. Donald Harvey, PharmD, FCCP, BCOP; Gary H. Lyman, MD, MPH, FASCO
FAQ Library
What are the recommended management strategies for patients with low-risk febrile neutropenia?
Christopher R. Flowers, MD

What is the incidence of febrile neutropenia (FN) in patients receiving chemotherapy?
R. Donald Harvey, III, PharmD, FCCP, BCOP

How do you define chemotherapy-related febrile neutropenia?
R. Donald Harvey, III, PharmD, FCCP, BCOP

What are the risk factors for the development of febrile neutropenia (FN) in patients receiving chemotherapy?
R. Donald Harvey, III, PharmD, FCCP, BCOP